title: The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients.
abstract: BACKGROUND
  As the incidence of prostate cancer continues to rise steeply, there is an increasing need to identify more accurate prognostic markers for the disease. There is some evidence that a higher modified Glasgow Prognostic Score (mGPS) may be associated with poorer survival in patients with prostate cancer but it is not known whether this is independent of other established prognostic factors. Therefore the aim of this study was to describe the relationship between mGPS and survival in patients with prostate cancer after adjustment for other prognostic factors.
  
  
  METHODS
  Retrospective clinical series on patients in Glasgow, Scotland, for whom data from the Scottish Cancer Registry, including Gleason score, Prostate Specific Antigen (PSA), C-reactive protein (CRP) and albumin, six months prior to or following the diagnosis, were included in this study.
  
  
  RESULTS
  Seven hundred and forty four prostate cancer patients were identified; of these, 497 (66.8%) died during a maximum follow up of 11.9 years. Patients with mGPS of 2 had poorest 5-year and 10-year relative survival, of 32.6% and 18.8%, respectively. Raised mGPS also had a significant association with excess risk of death at five years (mGPS 2: Relative Excess Risk = 3.57, 95% CI 2.31-5.52) and ten years (mGPS 2: Relative Excess Risk = 3.42, 95% CI 2.25-5.21) after adjusting for age, socioeconomic circumstances, Gleason score, PSA and previous in-patient bed days.
  
  
  CONCLUSIONS
  The mGPS is an independent and objective prognostic indicator for survival of patients with prostate cancer. It may be useful in determining the clinical management of patients with prostate cancer in addition to established prognostic markers.
authors.forename: Kashif
authors.initials: K
authors.lastname: Shafique
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Proctor
authors.forename: Donald C
authors.initials: DC
authors.lastname: McMillan
authors.forename: Hing
authors.initials: H
authors.lastname: Leung
authors.forename: Karen
authors.initials: K
authors.lastname: Smith
authors.forename: Billy
authors.initials: B
authors.lastname: Sloan
authors.forename: David S
authors.initials: DS
authors.lastname: Morrison
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D012189:Retrospective Studies; D015996:Survival Rate